1
|
Voland P, Barthel C, Azzouz B, Raison-Peyron N, Du-Thanh A, Staumont-Sallé D, Jachiet M, Soria A, Nosbaum A, Valois A, Leleu C, Lebrun-Vignes B, Trenque T, Hettler D, Bernier C, Viguier M. Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study. J Am Acad Dermatol 2023; 88:380-387. [PMID: 36252685 DOI: 10.1016/j.jaad.2022.10.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 09/27/2022] [Accepted: 10/01/2022] [Indexed: 11/05/2022]
Abstract
BACKGROUND Human immunoglobulins are used for treating diverse inflammatory and autoimmune disorders. Eczema is an adverse event reported but poorly described. OBJECTIVES To describe the clinical presentation, severity, outcome, and therapeutic management of immunoglobulin-associated eczema. METHODS This retrospective and descriptive study included a query of the French national pharmacovigilance database, together with a national call for cases among dermatologists. RESULTS We included 322 patients. Eczema occurred preferentially in men (78.9%) and in patients treated for neurological pathologies (76%). The clinical presentation consisted mainly of dyshidrosis (32.7%) and dry palmoplantar eczema (32.6%); 5% of cases exhibited erythroderma. Sixty-two percent of the eczema flares occurred after the first immunoglobulin course. Eczema was observed with 13 intravenous or subcutaneous immunoglobulin types and recurred in 84% of patients who maintained the same treatment and in 68% who switched the immunoglobulin type. After immunoglobulin discontinuation, 30% of patients still had persistent eczema. LIMITATIONS Retrospective study, with possible missing data or memory bias. CONCLUSION Immunoglobulin-associated eczema occurred with all immunoglobulin types, preferentially in patients with neurologic diseases who required prolonged immunoglobulin treatment. Recurrence was frequent, even after switching the immunoglobulin type, which can lead to a challenging therapeutic situation when immunoglobulin maintenance is required.
Collapse
Affiliation(s)
- Pauline Voland
- Dermatology Department, Robert-Debré Hospital, Reims-Champagne Ardennes University, IRMAIC, EA7509, Reims, France
| | - Camille Barthel
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Brahim Azzouz
- Regional Pharmacovigilance Center of Reims, Reims-Champagne Ardennes University, Reims, France
| | - Nadia Raison-Peyron
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - Aurélie Du-Thanh
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - Delphine Staumont-Sallé
- Department of Dermatology, Lille University Hospital Center, University of Lille, Lille, France
| | - Marie Jachiet
- University of Paris, Faculty of Medicine, Assistance Publique-Hôpitaux de Paris (APHP), Department of Dermatology, Saint-Louis Hospital, Paris, France
| | - Angèle Soria
- Sorbonne Université, Department of Dermatology and Allergy, Tenon Hospital, AP-HP, Paris, France
| | - Audrey Nosbaum
- Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Pierre-Bénite, France
| | - Aude Valois
- Dermatology Department, Army training hospital Sainte Anne, Toulon, France
| | - Camille Leleu
- Dermatology Department, Dijon University Hospital Center, Dijon, France
| | - Bénédicte Lebrun-Vignes
- Regional Pharmacovigilance Center, Pitié Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Thierry Trenque
- Regional Pharmacovigilance Center of Reims, Reims-Champagne Ardennes University, Reims, France
| | - Dominique Hettler
- Pharmacy and Pharmacovigilance Unit, Robert-Debré Hospital, Reims-Champagne Ardennes University, Reims, France
| | - Claire Bernier
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Manuelle Viguier
- Dermatology Department, Robert-Debré Hospital, Reims-Champagne Ardennes University, IRMAIC, EA7509, Reims, France.
| | | |
Collapse
|
2
|
Doyle C, Eustace K. Pompholyx as a side effect of intravenous immunoglobulin (IVIg). BMJ Case Rep 2022; 15:e248772. [PMID: 35354565 PMCID: PMC8968538 DOI: 10.1136/bcr-2022-248772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/14/2022] [Indexed: 11/04/2022] Open
Abstract
Intravenous immunoglobulin (IVIg) is increasingly used across multiple specialties for the treatment of inflammatory and autoimmune diseases. Cutaneous reactions to IVIg are generally minor. Pompholyx is a common eruption of small vesicles on the palms, soles, and/or lateral aspects of the fingers. It has a multifactorial aetiology but is rarely attributed to being a drug-related side effect. We describe a 43-year-old woman presenting with peripheral sensory neuropathy who developed pompholyx eczema on both palms following treatment with IVIg.
Collapse
|